The Role of COX-1 and COX-2 in Alzheimer's Disease Pathology and the Therapeutic Potentials of Non-Steroidal Anti-Inflammatory Drugs

Authors: Hoozemans, Jeroen J.M.¹; O'Banion, M. K.¹

Source: Current Drug Targets-CNS & Neurological Disorders, Volume 4, Number 3, June 2005 , pp. 307-315(9)

Publisher: Bentham Science Publishers

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Epidemiological studies indicate that anti-inflammatory drugs, especially the non-steroidal antiinflammatory drugs (NSAIDs), decrease the risk of developing Alzheimer's disease (AD). Their beneficial effects may be due to interference of the chronic inflammatory reaction in AD. The best-characterised action of NSAIDs is the inhibition of cyclooxygenase (COX). So far, clinical trials designed to inhibit inflammation or cyclooxygenase activity have failed in the treatment of AD patients. In this review we will focus on the role, expression and regulation of COX-1 and COX-2 in neurodegeneration and AD pathogenesis. Understanding the pathological, physiological and neuroprotective role of cyclooxygenase will contribute to the development of a therapy for the treatment or prevention of AD.

Keywords: alzheimers disease; cox; neuroinflammation; microglia; neuron; nsaids

Document Type: Review article

DOI: 10.2174/1568007054038201

Affiliations: 1: Academic Medical Center, Neurogenetics Laboratory, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands.

Your trusted access to this article has expired.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy